MADRIGAL PHARMACEUTICALS, INC. Long-Term Debt, Maturity, Year Five
MADRIGAL PHARMACEUTICALS, INC. (MDGL) had Long-Term Debt, Maturity, Year Five of $366.21 million as of 2025-12-31, per its 10-K filed 2026-02-19.
Financial Statements › Notes › Commitment and Contingencies › Long-Term Debt, Fiscal Year Maturity › Long-Term Debt, Maturity, Year Four and Five
us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive · last filed 2026-02-19
- 2025-12-31: Long-Term Debt, Maturity, Year Five $366.21M.
- 2025-09-30: Long-Term Debt, Maturity, Year Five $366.85M.
| Period end | Long-Term Debt, Maturity, Year Five |
|---|---|
| 2025-12-31 | $366.21M 10-K · filed 2026-02-19 |
| 2025-09-30 | $366.85M 10-Q · filed 2025-11-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |